Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Jun;15(6):509.
doi: 10.5152/akd.2015.6316. Epub 2015 May 22.

Possible renoprotective effects of dabigatran

Oğuz Karahan  1
Affiliations
Comment

Possible renoprotective effects of dabigatran

Oğuz Karahan. Anatol J Cardiol. 2015 Jun.
No abstract available

PubMed Disclaimer

Comment in

  • Author's reply.
    Altın C, Sakallıoğlu O, Gezmiş E, Müderrisoğlu H. Altın C, et al. Anatol J Cardiol. 2015 Jun;15(6):509-10. Anatol J Cardiol. 2015. PMID: 26258187 Free PMC article. No abstract available.

Comment on

References

    1. Altın C, Sakallıoğlu O, Gezmiş E, Müderrisoğlu H. A novel oral anticoagulant, dabigatran, in acute renal infarction. Anatol J Cardiol. 2015;15:158–9. [CrossRef] - PMC - PubMed
    1. DemirtaşS Karahan O, Yazıcı S, Güçlü O, Çalışkan A, Tezcan O, et al. Investigation of possible prophylactic, renoprotective, and cardioprotective effects of thromboprophylactic drugs against ischemia-reperfusion injury. Kaohsiung J Med Sci. 2015;31:115–22. [CrossRef] - PMC - PubMed
    1. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–72. [CrossRef] - PubMed
    1. Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, et al. American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:1144–50. [CrossRef] - PubMed
    1. Yazıcı S, Karahan O, Oral MK, Bayramoğlu Z, Ünal M, Çaynak B, et al. Comparison of renoprotective effect of dabigatran with low-molecular-weight heparin. Clin Appl Thromb Hemost. 2015 [CrossRef] - PubMed

LinkOut - more resources